Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 252

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 252
---
-------------:|:--|
| Principal amount |     | $ |       900 |   |     | $ |          900 |   |
| Discount rate    |     |   |        30 | % |     |   |           30 | % |
| Term (years)     |     |   | 0.75-0.92 |   |     |   |         0.25 |   |
| Fair value       |     |   |     2,538 |   |     |   |        7,405 |   |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy.

The Company recalculated the fair
value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM. As of June 30, 2024, a 5.0% decrease in discount
rate would increase the fair value of the 2020 Notes to $2,619; a 5.0% increase in discount rate would decrease the fair value of the
2020 Notes to $2,462.

The following table presents changes
in the fair value of the 2020 Notes and 2021 Notes:

| Balance as of December 31, 2023                        |     | $ |  7,405 |   |
| Changes in fair value                                  |     |   | (4,867 | ) |
| Balance as of June 30, 2024                            |     | $ |  2,538 |   |
| Balance as of December 31, 2022                        |     | $ |  6,472 |   |
| Conversion of the 2021 Notes into preferred D-1 shares |     |   | (1,086 | ) |
| Changes in fair value                                  |     |   |  2,114 |   |
| Balance as of June 30, 2023                            |     | $ |  7,500 |   |

<div align='center'>F-10</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 5: | WARRANT LIABILITY |

| a. | During 2015, the Company issued 66,946                                                   
 warrants in